The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredient
The teams are working to develop a formulation that meets regulatory and industrial requirements for bringing a commercial ingredient to market
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announced the progress of its collaborative program with Avril, a key player in the French oils and proteins sector. The tests validated the efficacy of the ingredient at a competitive dosage. The regulatory and industrial stages are underway for marketing purposes.
The collaborative program with AVRIL aims to develop a new range of ingredients for animal feed. These ingredients, produced by bacterial fermentation, aim to offer a biobased alternative to the livestock sector which is still dominated by petrochemical products.
The producing strain, selected from DEINOVE's library, was evaluated in a broader testing phase. The results validated the selected dosage and demonstrated that the ingredient is competitive with the reference products.
The product will be marketed as a raw material for animal feed. Regulatory proceedings are being initiated to this end.
The DEINOVE teams are finalizing the manufacturing process towards industrialization. The industrial-scale batch will be tested in real conditions at the end of the year.
The two partners aim to bring a first ingredient to market by the end of 2020.
" The animal feed market is waiting for innovative and biobased products that are more respectful of animal welfare and consumer concerns. We are proud to be moving forward with AVRIL in that direction " said Marie BÉZENGER, VP Operations at DEINOVE.